Hip Innovation Technology Leadership
Board of Directors
George Diamantoni, Chief Executive Officer, Manager and Chairman of the Board
George Diamantoni is currently the Chief Executive Officer, Manager and Chairman of the Board to Hip Innovation Technology, LLC. He is the Founder and Chief Executive Officer of Joint Innovation Technology, LLC, which is the holder of the majority of the Class A Membership Interests of the Company for which he provides executive leadership. Mr. Diamantoni has over 25 years of professional experience in the health care industry, including 20 years with The Upjohn Company, Pharmacia Corporation, Pfizer Inc., and Schering Plough Corporation, multinational pharmaceutical corporations, and 5 years with Allos Therapeutics, Inc., an oncology company; and Bone Care International, Inc., a specialty pharmaceutical company. Mr. Diamantoni has previously served as a consulting Partner for Direkt Finance, a privately held international investment firm. In this position, he established and led a health care-focused investment division. Mr. Diamantoni has held the offices of Vice President for Government Affairs, Strategic Alliances, Reimbursement and Managed Accounts, Customer Marketing, and Sales with his previous employers. He obtained his Bachelor of Arts in Biology and Chemistry from Kalamazoo College in Kalamazoo, Michigan.
James Caruso
James Caruso is a Senior Life Sciences Executive with a 27 year record of success with medical device start-up, mid-tier biotechnology, specialty and multinational pharmaceutical companies. He is currently the President and Chief Executive Officer of Cellectar Biosciences, Inc., an oncology company. Most recently, he served as our Executive Vice President and Chief Operating Officer. He was previously the Executive Vice President, Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company acquired by Spectrum Pharmaceuticals. Mr. Caruso was Senior Vice President, Sales and Marketing, at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation. Prior to that, Mr. Caruso was Vice President of Neuroscience Specialty Sales at Novartis, a pharmaceutical company. He served as Vice President, Sales, of BASF Pharmaceuticals-Knoll, a pharmaceutical company that was acquired by Abbott Corporation. For 12 years, Mr. Caruso held various commercial-focused positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Caruso earned a Bachelor of Science in Finance from the University of Nevada in 1988.
Kevin Sidow
Kevin Sidow has over 35 years of orthopaedic experience and is well known in the medical device industry. He currently has board positions on two other medical device companies. Most recent to his current board positions, he was President and Chief Executive Officer of Moximed, Inc. Prior to this role, he was President and CEO of St. Francis Medical Technologies, Inc. (SFMT). Founded in 1997, St. Francis Medical Technologies was a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies, Inc., was sold for $725 million to Kyphon Inc. Prior to joining SFMT, Mr. Sidow was the Worldwide President of DePuy Inc. As former Worldwide President of DePuy, his responsibilities included the combined worldwide reconstructive business (hips, knees, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion. Mr. Sidow holds a B.S. in Accounting from West Virginia University.
Zafer Termanini, M.D., F.A.C.S., President and Chief Medical Officer
Dr. Zafer Termanini is the company’s President and Chief Medical Officer. Dr. Termanini is a Fellow of the American College of Surgeons, and is certified by the American Board of Orthopaedic Surgery as an orthopaedic surgeon with over 30 years of experience. He is a member of the American Academy of Orthopaedic Surgeons. He is also a Diplomate of the American College of Disability Analysts and the American College of Forensic Examiners, with specialties in Orthopaedic and Joint Reconstruction, Sports Medicine and Biomechanical Analysis. Dr. Termanini, inventor of the Interlocking Reverse Hip, currently holds 8 U.S. patents and 6 U.S. patent applications. Five of his patents have been sold and successfully commercialized. He has served as Chief of Orthopaedic Surgery and General Surgery at East Orange General Hospital and has privileges in several New Jersey hospitals, including Newark Beth Israel Medical Center, Saint Barnabas Medical Center, and Meadowlands Hospital Medical Center. He is licensed in New Jersey, New York, and Georgia. Dr. Termanini received his C.P.E.M. degree, with honors, from the College Scientifique Universitaire in Angers, France, in 1967 and his medical degree, with honors, from the Université d’Angers in Angers, France, in 1973. He also attended the prestigious school of “Arts et Métiers” where he studied Biomechanical Engineering.
